{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:42:09Z","timestamp":1793835729578,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41591-024-03327-6","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T18:02:39Z","timestamp":1729879359000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Ellen M.","family":"Apperloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Gorriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-992X","authenticated-orcid":false,"given":"Secundino","family":"Cigarr\u00e1n Guldris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-8558","authenticated-orcid":false,"given":"Josep M.","family":"Cruzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jes\u00fas","family":"Puchades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"L\u00f3pez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4417-7732","authenticated-orcid":false,"given":"Femke","family":"Waanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-7115","authenticated-orcid":false,"given":"Gozewijn D.","family":"Laverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"van der Aart-van der Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Hoogenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0335-8177","authenticated-orcid":false,"given":"Andr\u00e9 P.","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobien","family":"Verhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3000-2229","authenticated-orcid":false,"given":"Sofia B.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-5883","authenticated-orcid":false,"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-5301","authenticated-orcid":false,"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z. I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Jongs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"3327_CR1","unstructured":"World Health Organization. Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2024)."},{"key":"3327_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"Non-Communicable Disease Risk Factor Collaboration.","year":"2024","unstructured":"Non-Communicable Disease Risk Factor Collaboration. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027\u20131050 (2024).","journal-title":"Lancet"},{"key":"3327_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"Global Burden Disease Collaborators.","year":"2023","unstructured":"Global Burden Disease Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"3327_CR4","doi-asserted-by":"crossref","unstructured":"Kovesdy, C. P., Furth, S. L. & Zoccali, C & World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. Kidney Int. 91, 260\u2013262 (2017).","DOI":"10.1016\/j.kint.2016.10.019"},{"key":"3327_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.kint.2016.12.013","volume":"91","author":"C Garofalo","year":"2017","unstructured":"Garofalo, C. et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 91, 1224\u20131235 (2017).","journal-title":"Kidney Int."},{"key":"3327_CR6","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1152\/ajpendo.00179.2022","volume":"324","author":"Z Jiang","year":"2023","unstructured":"Jiang, Z. et al. Obesity and chronic kidney disease. Am. J. Physiol. Endocrinol. Metab. 324, E24\u2013E41 (2023).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"3327_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","volume":"15","author":"JE Hall","year":"2019","unstructured":"Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z. & Hall, M. E. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat. Rev. Nephrol. 15, 367\u2013385 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"3327_CR8","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group.","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"3327_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group.","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1\u2013S127 (2022).","journal-title":"Kidney Int."},{"key":"3327_CR10","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1681\/ASN.2020050723","volume":"31","author":"M Oshima","year":"2020","unstructured":"Oshima, M. et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J. Am. Soc. Nephrol. 31, 2925\u20132936 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3327_CR11","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw, D. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 65, 2309\u20132320 (2004).","journal-title":"Kidney Int."},{"key":"3327_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/dom.12600","volume":"18","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink, H. J. et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obes. Metab. 18, 169\u2013177 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"3327_CR13","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos, E. D., Bakris, G. L., Rodbard, H. W. & Tuttle, K. R. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am. J. Prev. Cardiol. 14, 100502 (2023).","journal-title":"Am. J. Prev. Cardiol."},{"key":"3327_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605\u2013628 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"3327_CR15","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3327_CR16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3327_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3327_CR18","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun, H. M. et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. 30, 2058\u20132066 (2024).","journal-title":"Nat. Med."},{"key":"3327_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2337\/dc22-1889","volume":"46","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials. Diabetes Care 46, 801\u2013810 (2023).","journal-title":"Diabetes Care"},{"key":"3327_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman, A. M. et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145, 575\u2013585 (2022).","journal-title":"Circulation"},{"key":"3327_CR21","doi-asserted-by":"crossref","unstructured":"Apperloo, E. M. et al. Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. Nephrol. Dial. Transplant. gfae150 (2024).","DOI":"10.1093\/ndt\/gfae150"},{"key":"3327_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605\u2013617 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3327_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 7, 128\u2013139 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3327_CR24","doi-asserted-by":"publisher","unstructured":"Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03133-0 (2024).","DOI":"10.1038\/s41591-024-03133-0"},{"key":"3327_CR25","doi-asserted-by":"publisher","unstructured":"Neuen, B. L. et al. Cardiovascular, kidney and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.071689 (2024).","DOI":"10.1161\/CIRCULATIONAHA.124.071689"},{"key":"3327_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo, E. M. et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 12, 545\u2013557 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3327_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10, 774\u2013785 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3327_CR28","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/dom.13668","volume":"21","author":"KR Tuttle","year":"2019","unstructured":"Tuttle, K. R. et al. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Diabetes Obes. Metab. 21, 1493\u20131497 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"3327_CR29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2337\/dc23-0261","volume":"46","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on cystatin c-based kidney function: a SURPASS-4 post hoc analysis. Diabetes Care 46, 1501\u20131506 (2023).","journal-title":"Diabetes Care"},{"key":"3327_CR30","unstructured":"Diabetes Care (American Diabetes Association, accessed 1 September 2024); https:\/\/diabetesjournals.org\/diabetes\/issue\/73\/Supplement_1"},{"key":"3327_CR31","doi-asserted-by":"publisher","first-page":"e0163907","DOI":"10.1371\/journal.pone.0163907","volume":"11","author":"K Li","year":"2016","unstructured":"Li, K. et al. Effects of bariatric surgery on renal function in obese patients: a systematic review and meta analysis. PLoS ONE 11, e0163907 (2016).","journal-title":"PLoS ONE"},{"key":"3327_CR32","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1007\/s11695-018-3416-4","volume":"28","author":"SC Bilha","year":"2018","unstructured":"Bilha, S. C. et al. The effects of bariatric surgery on renal outcomes: a systematic review and meta-analysis. Obes. Surg. 28, 3815\u20133833 (2018).","journal-title":"Obes. Surg."},{"key":"3327_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.nephro.2016.10.002","volume":"13","author":"M Clerte","year":"2017","unstructured":"Clerte, M. et al. The measured glomerular filtration rate (mGFR) before and 6 months after bariatric surgery: a pilot study. Nephrol. Ther. 13, 160\u2013167 (2017).","journal-title":"Nephrol. Ther."},{"key":"3327_CR34","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2337\/db23-0455","volume":"73","author":"S Fawaz","year":"2024","unstructured":"Fawaz, S. et al. Adiponectin reduces glomerular endothelial glycocalyx disruption and restores glomerular barrier function in a mouse model of type 2 diabetes. Diabetes 73, 964\u2013976 (2024).","journal-title":"Diabetes"},{"key":"3327_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4239\/wjd.v3.i1.1","volume":"3","author":"AN Sasson","year":"2012","unstructured":"Sasson, A. N. & Cherney, D. Z. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J. Diabetes 3, 1\u20136 (2012).","journal-title":"World J. Diabetes"},{"key":"3327_CR36","doi-asserted-by":"publisher","first-page":"100804","DOI":"10.1016\/j.xkme.2024.100804","volume":"6","author":"A Chagnac","year":"2024","unstructured":"Chagnac, A. & Friedman, A. N. Measuring albuminuria in individuals with obesity: pitfalls of the urinary albumin-creatinine ratio. Kidney Med. 6, 100804 (2024).","journal-title":"Kidney Med."},{"key":"3327_CR37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3327_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130, 461\u2013470 (1999).","journal-title":"Ann. Intern. Med."},{"key":"3327_CR39","doi-asserted-by":"publisher","first-page":"981","DOI":"10.4155\/bio-2020-0122","volume":"12","author":"J Stevens","year":"2020","unstructured":"Stevens, J. et al. UHPLC-MS\/MS method for iohexol determination in human EDTA and lithium-heparin plasma, human urine and in goat- and pig EDTA plasma. Bioanalysis 12, 981\u2013990 (2020).","journal-title":"Bioanalysis"},{"key":"3327_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle, K. R. et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 403, 379\u2013390 (2024).","journal-title":"Lancet"},{"key":"3327_CR41","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-8587(18)30289-4","volume":"6","author":"D de Zeeuw","year":"2018","unstructured":"de Zeeuw, D. et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 6, 925\u2013933 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3327_CR42","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402, 2004\u20132017 (2023).","journal-title":"Lancet"},{"key":"3327_CR43","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","volume":"25","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink, H. J. L. et al. Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials. J. Am. Soc. Nephrol. 25, 1227\u20131239 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3327_CR44","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584\u20131594 (2023).","journal-title":"Lancet"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03327-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03327-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03327-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:05:24Z","timestamp":1737500724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03327-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3327"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03327-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M., F.W., J.M.C., M.L.-M., J.V., K.H. and A.v.d.A. report no conflicts of interest. J.L.G. declares funding to conduct clinical trials from AstraZeneca, Bayer, Boehringer Ingelheim and Novo Nordisk (all to the INCLIVA Research Institute); consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim and Novo Nordisk; and payment of honoraria for lectures from AstraZeneca, Novo Nordisk, Bayer, Menarini, Boehringer Ingelheim and Eli Lilly. N.J. received travel support from AstraZeneca. S.C.G. declares funding to conduct clinical trials from AstraZeneca, Bayer, Boehringer Ingelheim and Novo Nordisk (all to the FIDES Research Foundation) and payment of honoraria for lectures from AstraZeneca, Novo Nordisk, Baxter, Chiesi, ChemoCentrix, Clarion and Boehringer Ingelheim. M.J.P. received board speaker fees and travel expenses from AstraZeneca, NovoNordisk, Boehringer Ingelheim, Eli Lilly, Bayer and Menarini. G.D.L. received lecture fees from Sanofi, AstraZeneca and Janssen and has served as a consultant for AbbVie, Sanofi, Novo Nordisk, AstraZeneca, Boehringer Ingelheim and Merck Sharp & Dohme. A.v.B. declares being contracted via the University of Groningen (no personal payment) to undertake consultancy for Novo Nordisk, Eli Lilly and Boehringer Ingelheim. D.Z.I.C. has received honoraria from Boehringer Ingelheim, Eli Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometic, Bristol Myers Squibb, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene and Novo Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim, Eli Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo Nordisk. S.B.A. reports no conflicts of interest. She receives research support from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. R.E.S. received grants to the institution from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim and NovoNordisk and speaker and advisor honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Servier and TAD. C.W. has received grants and served on steering committees for Boehringer Ingelheim; served on advisory boards for Boehringer Ingelheim, Merck Sharp & Dohme and Bayer; and received lecture fees from Boehringer Ingelheim, Eli Lilly, AstraZeneca, Merck Sharp & Dohme, Novo Nordisk and Bayer. H.J.L.H. is a consultant for AstraZeneca, Alexion, Bayer, Boehringer Ingelheim, CSL-Behring, DIMERIX, Eli Lilly, Gilead, Janssen, Novartis, Novo Nordisk, Roche, Travere Pharmaceuticals and VIFOR Pharma. He received research support through his institution from AstraZeneca, Boehringer Ingelheim, Janssen and Novo Nordisk. He received lecture fees from AstraZeneca, Bayer and Novo Nordisk.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}